Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

MSD also sells an older shot called Pneumovax 23, which covers 23 serotypes, but is based on an older polysaccharide technology that does not stimulate the immune response as strongly as the newer ...

Wierzbowski A, Pless R, Hildebrand KJ on behalf of the National Advisory Committee on Immunization (NACI). Summary of the NACI Statement on Public Health Level Recommendations on the Use of ...